Jong-Mu Sun

11PUBLICATIONS
56CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Feb 06, 2026
JIN-A02, a Mutant-Selective Fourth-Generation EGFR Inhibitor, Overcomes C797S-Mediated Resistance and Demonstrates Intracranial Activity in NSCLC.

Eun Ji Lee, Ji Ae Ko, Min-Je Kim

|Oct 31, 2025
Artificial intelligence-powered spatial analysis of tumor microenvironment in patients with non-small cell lung cancer with acquired resistance to EGFR tyrosine kinase inhibitor.

Yeong Hak Bang, Geun-Ho Park, Jin Woo Oh

|Oct 29, 2024
TROPION-Lung07: Phase III study of Dato-DXd + pembrolizumab ± platinum-based chemotherapy as 1L therapy for advanced non-small-cell lung cancer.

Isamu Okamoto, Shoichi Kuyama, Nicolas Girard

|Jun 24, 2024
Practice pattern and risk of not receiving planned surgery after neoadjuvant chemoradiotherapy for locally advanced oesophageal squamous cell carcinoma.

Tae Hee Hong, Tae Ho Kim, Genehee Lee

|Jan 02, 2024
Immune checkpoint inhibitor use and the incidence of hepatitis B virus reactivation or immune-related hepatitis in non-small cell lung cancer patients with chronic hepatitis B.

Joohyun Hong, Jiyun Lee, Sehhoon Park

|Jul 15, 2022
Clinical, Pathologic, and Molecular Prognostic Factors in Patients with Early-Stage EGFR-Mutant NSCLC.

Hyun Ae Jung, Jinyeong Lim, Yoon-La Choi

Pageof 2

Frequent Collaborators

3 joint publications

Myung-Ju Ahn

2 joint publications

Han Gyul Yoon

2 joint publications

Dongryul Oh

2 joint publications

Jae Myoung Noh